Free tool
FAERS Monitor: Canasa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021252 or its brand name (Canasa, Mesalamine). Reports on generic versions are filed under their own applications.
Reports
28,963
Serious
25,161
87% of reports
Hospitalization
9,606
Death reported
1,991
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use6,585
- colitis ulcerative4,668
- drug ineffective4,551
- condition aggravated3,424
- diarrhoea2,723
- haematochezia2,523
- fatigue2,332
- abdominal pain2,214
- weight decreased1,988
- headache1,960
- nausea1,929
- pyrexia1,863
- frequent bowel movements1,840
- pain1,709
- intentional product use issue1,681
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 109 |
| 2005 | 154 |
| 2006 | 113 |
| 2007 | 159 |
| 2008 | 580 |
| 2009 | 150 |
| 2010 | 292 |
| 2011 | 725 |
| 2012 | 662 |
| 2013 | 232 |
| 2014 | 294 |
| 2015 | 374 |
| 2016 | 466 |
| 2017 | 483 |
| 2018 | 683 |
| 2019 | 827 |
| 2020 | 1,226 |
| 2021 | 2,470 |
| 2022 | 4,197 |
| 2023 | 4,314 |
| 2024 | 4,054 |
| 2025 | 4,005 |
| 2026 | 2,393 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,025,196 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| colitis ulcerativeSignal | 4,668 | 84.6 | 82.2 | 345,883 |
| frequent bowel movementsSignal | 1,840 | 53.0 | 50.6 | 87,555 |
| haematocheziaSignal | 2,523 | 34.7 | 33.4 | 79,058 |
| intentional product use issueSignal | 1,681 | 14.2 | 13.5 | 20,283 |
| condition aggravatedSignal | 3,424 | 8.3 | 8.0 | 21,913 |
| abdominal painSignal | 2,214 | 7.0 | 6.7 | 11,329 |
| off label useSignal | 6,585 | 5.5 | 5.4 | 25,070 |
| weight decreasedSignal | 1,988 | 5.2 | 5.0 | 6,784 |
| pyrexiaSignal | 1,863 | 3.9 | 3.8 | 4,105 |
| diarrhoeaSignal | 2,723 | 3.1 | 3.0 | 3,908 |
| drug ineffectiveSignal | 4,551 | 2.5 | 2.4 | 4,406 |
| headacheSignal | 1,960 | 2.3 | 2.2 | 1,436 |
| fatigueSignal | 2,332 | 2.2 | 2.1 | 1,538 |
| painSignal | 1,709 | 2.0 | 1.9 | 907 |
| nausea | 1,929 | 1.8 | 1.7 | 671 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.